8-K: BioXcel's BXCL501 Shows Strong At-Home Efficacy Correlation

BioXcel Therapeutics announced positive results from a correlation study supporting the use of a modified scale for assessing acute agitation in at-home settings, paving the way for a Q1 2026 sNDA submission.

Summary

• BioXcel Therapeutics announced positive results from a correlation study related to exploratory efficacy outcomes from the SERENITY At Home trial on October 14, 2025.
• The study assessed the correlation between the standard clinician-administered Positive and Negative Syndrome Scale – Excited Component (PEC) and the patient/caregiver-rated modified CGI-S (mCGI-S) scale in 33 patients.
• A statistically significant and strong correlation was observed, with a correlation of =0.89 (p<0.0001) for patient assessments and =0.88 (p<0.0001) for caregiver (informant) assessments.
• The mCGI-S scale was developed in consultation with the FDA to enable assessment of BXCL501's continued clinical effect with repeat dosing in an at-home setting.
• No serious adverse events were reported, and the safety profile remains consistent with the IGALMI label.
• These results, along with the data from the SERENITY At Home trial, will be included in a supplemental New Drug Application (sNDA) submission planned for the first quarter of 2026.

Sentiment

Score: 8

Explanation: The positive correlation study results are a significant step towards expanding BXCL501's utility to at-home settings, which could broaden its market and improve patient access. The strong statistical significance and consistent safety profile are highly favorable for regulatory submission.

Positives

• Demonstrated a statistically significant and strong correlation between clinician-administered PEC and patient/caregiver-rated mCGI-S (patient: =0.89; p<0.0001, informant: =0.88; p<0.0001).
• The strong correlation provides crucial support for using mCGI-S to assess efficacy in the outpatient setting, which is essential for at-home treatment of acute agitation.
• No serious adverse events were reported, maintaining a safety profile consistent with the IGALMI label.
• The positive results enable the planned sNDA submission for BXCL501 in Q1 2026, potentially expanding its use to at-home settings for acute agitation associated with schizophrenia and bipolar disorder.

Risks

• Limited operating history.
• Incurrence of significant losses.
• Need for substantial additional funding and ability to raise capital when needed.
• Impact of reprioritization.
• Significant indebtedness, ability to comply with covenant obligations, and potential payment obligations related to such indebtedness and other contractual obligations.
• Conditions and events that raise substantial doubt about the ability to continue as a going concern.
• Limited experience in drug discovery and drug development.
• Risks related to the TRANQUILITY program.
• Dependence on the success and commercialization of IGALMI, BXCL501, BXCL502, BXCL701, BXCL702, and other product candidates.
• The number of episodes of agitation and the size of the total addressable market may be overestimated, and approval that may be obtained may be based on a narrower definition of the patient population.
• Lack of experience in marketing and selling drug products.
• Risk that IGALMI or product candidates may not be accepted by physicians or the medical community in general.
• Extensive and ongoing regulatory requirements and obligations for IGALMI.
• Failure of preliminary data from clinical studies to predict final study results.
• Failure of early clinical studies or preclinical studies to predict future clinical studies.
• Ability to receive regulatory approval for product candidates.
• Ability to enroll patients in clinical trials.
• Undesirable side effects or potential of misuse of product candidates that could impact regulatory approval.
• Novel approach to the discovery and development of product candidates based on EvolverAI or AI platform.
• Significant influence of and dependence on BioXcel LLC.
• Failure to maintain compliance with Nasdaq's listing standards.
• Exposure to patent infringement lawsuits.
• Reliance on third parties.
• Ability to comply with the extensive regulations applicable to it.
• Impacts from data breaches or cyber-attacks, if any.
• Risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters.
• Risks associated with federal, state or foreign health care fraud and abuse laws.
• Ability to commercialize product candidates.

Future Outlook

The company plans to include the positive correlation study results and SERENITY At Home trial data in a supplemental New Drug Application (sNDA) submission for BXCL501, anticipated in the first quarter of 2026, aiming to expand its use to at-home settings.

Management Comments

• Management believes the strong correlation between clinician and patient/caregiver assessments supports the use of mCGI-S for evaluating BXCL501's efficacy in outpatient settings, paving the way for an sNDA submission.

Industry Context

This development is a significant step for at-home treatment options for acute agitation, aligning with broader industry trends towards decentralized clinical trials and patient-centric care. It could differentiate BXCL501 in the market by offering a more flexible and accessible administration option, potentially expanding its market reach and improving patient adherence.

Stakeholder Impact

• Shareholders: Positive news regarding clinical development could increase investor confidence and potentially share price due to expanded market potential.
• Patients: Potential for a more convenient and accessible at-home treatment option for acute agitation associated with schizophrenia and bipolar disorder.
• Caregivers: The mCGI-S scale allows caregivers to assess efficacy, potentially easing the burden of in-clinic visits and improving patient management.
• FDA: The company consulted with the FDA on the development of the mCGI-S scale, indicating a collaborative approach to regulatory approval for at-home use.

Next Steps

• Include the correlation study results and SERENITY At Home trial data in a supplemental New Drug Application (sNDA) submission.
• Planned sNDA submission in the first quarter of 2026.

Key Dates

Recommendation

The strong positive results from the correlation study for BXCL501's at-home efficacy assessment tool (mCGI-S) significantly de-risk the planned sNDA submission for Q1 2026. This development opens a crucial pathway for expanding the drug's market to outpatient settings, which represents a substantial growth opportunity and addresses a significant unmet need for patient convenience and accessibility. The consistent safety profile further strengthens the investment thesis, suggesting a favorable regulatory outcome and potential for increased revenue streams.

Keywords

BioXcel Therapeutics, BXCL501, SERENITY At Home, sNDA, acute agitation, schizophrenia, bipolar disorder, mCGI-S, PEC, clinical trial results, FDA, pharmaceutical, biotechnology